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Abstract
Severe intestinal graft-vs-host disease (GVHD) after allogeneic hematopoietic cell trans-
plantation (HCT) causes mucosal ulceration and induces innate and adaptive immune
responses that amplify and perpetuate GVHD and the associated barrier dysfunction. Phar-
macological agents to target mucosal barrier dysfunction in GVHD are needed. We hypothe-
sized that induction of Wnt signaling by lithium, an inhibitor of glycogen synthase kinase
(GSK3), would potentiate intestinal crypt proliferation and mucosal repair and that inhibition
of GSK3 in inflammatory cells would attenuate the deregulated inflammatory response to
mucosal injury. We conducted an observational pilot study to provide data for the potential
design of a randomized study of lithium. Twenty patients with steroid refractory intestinal
GVHD meeting enrollment criteria were given oral lithium carbonate. GVHD was otherwise
treated per current practice, including 2 mg/kg per day of prednisone equivalent. Seventeen
patients had extensive mucosal denudation (extreme endoscopic grade 3) in the duodenum
or colon. We observed that 8 of 12 patients (67%) had a complete remission (CR) of GVHD
and survived more than 1 year (median 5 years) when lithium administration was started
promptly within 3 days of endoscopic diagnosis of denuded mucosa. When lithium was
started promptly and less than 7 days from salvage therapy for refractory GVHD, 8 of 10
patients (80%) had a CR and survived more than 1 year. In perspective, a review of 1447
consecutive adult HCT patients in the preceding 6 years at our cancer center showed 0%
one-year survival in 27 patients with stage 3–4 intestinal GVHD and grade 3 endoscopic
appearance in the duodenum or colon. Toxicities included fatigue, somnolence, confusion
or blunted affect in 50% of the patients. The favorable outcomes in patients who received
prompt lithium therapy appear to support the future conduct of a randomized study of lithium
for management of severe GVHD with extensive mucosal injury.
Trial Registration: ClinicalTrials.gov NCT00408681
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Introduction
Acute graft-versus-host disease (GVHD), driven by alloreactive donor T cells, remains a signif-
icant complication of allogeneic hematopoietic cell transplantation (HCT). Among acute
GVHD targets, intestinal involvement is the main source of morbidity and mortality [1]. The
histological hallmark of intestinal GVHD is apoptosis of epithelial cells at the crypt base and
secondary dropout of cells and crypts [2,3]. At the extreme severity GVHD results in progres-
sive crypt loss and mucosal denudation of large segments of the intestine [4–6]. In our experi-
ence, mucosal recovery and survival at this stage are distinctly rare outcomes [1,5,7,8].
Steroid refractory intestinal GVHD is increasingly viewed as resembling a barrier dysfunc-
tion disorder characterized by an anatomic or physiologic barrier defect and a dysregulated
immune response, resulting in a self-perpetuating cycle of chronic inflammation and barrier
disruption [9–12]. In GVHD, the underlying defect is the immune mismatch between recipi-
ent and donor [4]. Mucosal injury results in exposure to luminal microbiota and damage asso-
ciated molecular patterns that induce an inflammatory and cytokine cascade mediated by
pattern recognition receptors and antigen presenting cells [9,13–18]. Aberrant toll-like recep-
tor signaling, including a proinflammatory response to commensal bacteria, as well as dysre-
gulated mucosal repair and dysbiosis contribute to this process [11,13,19–21]. The mucosal
inflammation amplifies and perpetuates systemic GVHD and sustains the targeting of intesti-
nal epithelium by effector immune cells and cytokines [22,9]. The clinical challenge is to sup-
port the immunosuppressed patient with a denuded mucosal barrier until adequate mucosal
regeneration and resolution of mucosal inflammation have occurred. Current treatment of
severe GVHD, utilizing broad spectrum immunosuppression, targets systemic GVHD but
generally fails to resolve the mucosal pathology. Therapeutic agents to induce mucosal regen-
eration and specifically target the mucosal inflammatory cycle are lacking.
The study of lithium in patients with severe GVHD and mucosal denudation was based on
the hypotheses that induction of Wnt signaling by lithium would potentiate intestinal crypt
proliferation and mucosal healing and that inhibition of GSK3 in inflammatory cells would
modulate the proinflammatory response to mucosal barrier dysfunction. Landmark studies
have established that Wnt signaling, including the downstream β-catenin/Tcf4-mediated tran-
scription, is essential for epithelial stem cell replication, crypt genesis and crypt proliferation
[23,24]. Inhibition of Wnt, β-catenin or Tcf4 in animal models results in loss of intestinal
crypts and in mucosal denudation [24–27]. Conversely, induction of Wnt signaling in vitro
and in animal models results in proliferative epithelium [28,29]. In addition, it has been shown
by Hans Clevers’ group that self-renewing intestinal crypt organoids can be generated in vitro
by induction of Wnt signaling in isolated intestinal stem cells [30]. Induction of Wnt signaling
by the recombinant Wnt agonist R-spondin1 has also been shown to repair radiation-induced
intestinal mucosal injury and thereby suppress systemic GVHD in a rat model of HCT [31].
These observations demonstrated that systemic GVHD can be resolved by anatomic repair of
mucosal barrier disruption, and that mucosal repair can be enhanced by induction of Wnt
signaling.
Lithium is an inhibitor of glycogen synthase kinase 3 (GSK3), a constitutively active protein
kinase with diverse substrates, which is also the key regulator of cytosolic β-catenin [32]. Inhi-
bition of GSK3 by lithium promotes β-catenin/Tcf4-mediated transcription, the nuclear effec-
tor pathway of Wnt signaling [33,34] GSK3 inhibition was also shown to expand the crypt
epithelial stem cell niche in vitro by modulating paneth cell and stem cell signaling [29,35]
In addition to potentiating Wnt signaling, lithium has antiinflammatory effects in experi-
mental settings attributable to inhibition of GSK3 [36–40]. A large body of data indicates a role
for GSK3 in modulating innate immune responses, including promotion of proinflammatory
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nuclear factor kappa-B (NF-κB)-mediated signaling [41–43]. Physiologically phosphorylated
(kinase-inactive) GSK3 and experimentally inhibited GSK3 can induce the association of
cAMP response element–binding protein (CREB) to the nuclear coactivator CREB–binding
protein (CBP) and decrease the association of NF-κB p65 with CBP, thereby augmenting IL-10
production while reducing proinflammatory cytokine expression [36,43–46]. Inhibition of
GSK3 can modulate dysregulated toll-like receptor signaling, as in disrupted, inflamed mucosa,
to restore anti-inflammatory cytokine response [37,45,46]. Lithium and other GSK3 inhibitors
had protective effects in experimental animal models of enteritis and colitis [36,46–49]. attrib-
uted to both anatomic tissue repair and to antiinflammatory effects. Recently, GSK3 inhibition
was also shown to prevent lethal GVHD in a humanized xenograft model in mice [50].
Our observational study of lithium explored a new approach to the treatment of severe
GVHD focused on restoration of mucosal barrier function. As such, it was intended to provide
preliminary data to guide the design of a randomized clinical trial of lithium for potential stim-
ulation of intestinal mucosal recovery and resolution of mucosal inflammation in patients
with severe intestinal GVHD and extensively denuded intestinal mucosa.
Patients and methods
Study design
This was an open-label, single arm, observational pilot study conducted among allogeneic
HCT recipients 18 years of age and aimed to provide preliminary observations to potentially
guide the design of a structured, randomized clinical trial of lithium. Patients were enrolled
between July 18 2006 and August 31, 2010, and followed to May 1, 2015, or to date of death, if
earlier. All aspects of the study, including recruitment, monitoring and data collection were
conducted at the Fred Hutchinson Cancer Research Center (FHCRC) outpatient and hospital
facilities (the Seattle Cancer Care Alliance and University of Washington Medical Center in
Seattle, Washington). The study was approved by the FHCRC Institutional Review Board
(Protocol 2080.00, June 28, 2006). The clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki. Written informed consent was obtained
from all the participants. The study was submitted to NCI’s Physician Data Query (PDQ) for
registration on August 11, 2006 after we established that patient recruitment to the pilot study
was feasible, and was registered by PDQ at www.clinicaltrials.gov, # NCT00408681, on Decem-
ber 6, 2006. There are no ongoing or related trials of Lithium in patients with GVHD at the
FHCRC.
The protocol for this trial and supporting TREND checklist are available as Supporting
Information (S1 Checklist and S2 Protocol).
Eligibility and recruitment
Patients were eligible for inclusion in the study if they had a) denuded intestinal mucosa caused
by GVHD, defined as ulceration or sloughing of the epithelium in at least one third of the sur-
face area in a 30 cm colonic segment (i.e., rectosigmoid, descending or transverse colon) or in at
least one fifth of the surface area of the second portion of the duodenum, as estimated by endo-
scopic evaluation and imaging, or b) a clinical diagnosis of persistent severe intestinal GVHD
after initial treatment with glucocorticoids for at least 7 days as measured by stool volumes>
500 mL per day or persistent hemorrhage detectable by visual inspection of the stool.
Patients were ineligible for the study if they had significant renal dysfunction (estimated
GFR< 30 mL/min), persistent or recurrent malignancy, presence of a primary cause of intesti-
nal symptoms or ulceration other than GVHD, or any psychological condition potentially lim-
iting treatment or compliance.
Li to restore barrier function in GVHD
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Patients with denuded intestinal mucosa were identified by the FHCRC endoscopists (GS,
DH, GBM) and the transplant teams and referred to the study coordinator for evaluation. A
rigorous attempt was made to identify and refer all patients with denuded mucosa who pre-
sented during the study period by monitoring all endoscopies in this period. In addition, a few
patients with severe intestinal GVHD were selected by the transplant teams and referred for
evaluation by the study coordinator. Referred patients who met eligibility criteria and provided
consent were enrolled in the study. All patients identified to have denuded mucosa in our
institution during the study period who met eligibility criteria and consented to the study were
enrolled and evaluated for outcome. One thousand seven hundred and twelve adult allogeneic
HCT were performed at the FHCRC during the study period. All transplant patients are closely
monitored for outcome by the FHCRC teams.
Fig 1 illustrates the patient flow for patients with denuded mucosa. Twenty five patients
with denuded intestinal mucosa were identified and referred to the study. Six were excluded,
of whom 4 did not meet eligibility criteria and 2 refused consent. Three of the six also chose
hospice care. Two patients were taken off study due to diagnosis of adenovirus infection on
baseline endoscopy in one patient, and early relapse of AML requiring chemotherapy in
another. The latter patient is included in the drug safety reporting.
Five patients without denuded mucosa were selected by the transplant teams based on the
impression of severe GVHD and referred for study enrollment. Following enrollment, one
patient was retrospectively noted to not have met study eligibility criteria and was not evalu-
ated for outcome measures other than safety reporting. This patient had intact mucosa and
mild GVHD responsive to low dose prednisone at 1 mg/kg/d, which was started after the base-
line endoscopy. Another patient was diagnosed with adenovirus infection at baseline, a study
exclusion criterion, and taken off study. Three patients with intact mucosa were eligible for
outcome evaluation. The large majority of patients with severe GVHD and intact mucosa seen
at our institution during the study period were not referred to the study. S1 Fig illustrates the
patient flow for patients with intact intestinal mucosa.
Administration of lithium
In addition to treatment of GVHD, study patients received extended-release lithium carbonate
tablets (450 mg) starting at 450 mg orally per day. Initially the dose was adjusted, up to 3 doses
daily, to maintain the serum lithium trough concentration at 0.8 to 1.2 mmol/L. Subsequently,
the dose was restricted to once or twice daily and adjusted to maintain serum concentrations
of 0.5 to 1.0 mmol/L after we observed dulled affect at higher concentrations. Serum lithium
concentrations were monitored beginning at one week after the first dose. Lithium was admin-
istered by the nursing staff in the hospital setting for the full duration in 9 patients and for the
initial 12–49 days in 11 patients. Medication was self-administered in the outpatient setting.
The timing of initiation and the duration of lithium administration were at the discretion
of the patient care team and were not dictated by the study protocol. The duration of lithium
administration was limited to 8 weeks, with the option to extend administration outside the
auspices of the protocol. Cessation of lithium administration was required in the event of sig-
nificant toxicity, including renal dysfunction (estimated GFR< 30 mL/min) or recurrent or
secondary malignancy.
Prophylaxis and treatment of GVHD
Individualized GVHD therapy was prescribed by the patient care team. Current practice at the
time of the study included GVHD prophylaxis with a calcineurin inhibitor (cyclosporine or
tacrolimus) in combination with either methotrexate or mycophenolate mofetil (MMF) after
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myeloablative conditioning. A calcineurin inhibitor in combination with MMF was used after
reduced intensity conditioning. Patients with HLA-haploidentical donors also received high-
dose cyclophosphamide after HCT. Initial treatment of acute GVHD generally consisted of
corticosteroids at a prednisone-equivalent dose of 1–2 mg/kg/day, depending on the severity,
and continued administration of a calcineurin inhibitor. Most patients also received oral
beclomethasone dipropionate in corn oil with or without oral enteric-coated budesonide.
Other immunosuppressive agents were added at the discretion of the patient care team if
patients had an unsatisfactory response or rapid progression of severe symptoms. MMF (or
enteric coated mycophenolic acid) and sirolimus were often used in this setting. Agents with a
high toxicity profile or poorly defined efficacy profile were reserved for severe GVHD consid-
ered to be refractory or unlikely to respond to standard measures. For the purpose of the study
Fig 1. Flow chart of patients with denuded intestinal mucosa.
https://doi.org/10.1371/journal.pone.0183284.g001
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reporting, these agents are designated as “salvage therapy” and include infliximab, etanercept,
rabbit or horse antithymocyte globulin, alemtuzumab, pentostatin, extracorporeal photopher-
esis, and a clinical trial of mesenchymal stem cells versus placebo.
Patients were considered to have corticosteroid-refractory GVHD if they experienced 3
days with progressive manifestations of GVHD, 1 week with persistent, unimproving grade 3
GVHD or inability to taper steroids after 2 weeks, during treatment at prednisone-equivalent
dose of 2 mg/kg or higher. Patients treated with salvage therapy in addition to steroids at 2
mg/kg were also considered to have corticosteroid-refractory GVHD.
Evaluations
Study evaluations included patient interviews and review of the patient’s clinical course and
laboratory, histologic and endoscopic findings. Endoscopic evaluations were performed only
as clinically indicated and were not prescribed by the study protocol. Medical records were
reviewed by study personnel to monitor for adverse events.
End points
The primary endpoints, in addition to safety, were the clinical response of GVHD among all
patients and the mucosal response in the subset of patients with endoscopically documented
denuded intestinal mucosa, among patients who received lithium for at least 28 days. Assess-
ment of survival and informal comparison to historical data was also planned.
Criteria for clinical response
Complete response (CR) of intestinal GVHD was defined as the absence of any symptoms
referable to intestinal GVHD. Partial response (PR) was defined as clearing of abdominal pain
(or withdrawal of opioid analgesic requirements in patients treated for abdominal pain) and of
grossly visible bleeding if present, and resolution of diarrhea or decrease in the three day aver-
age stool volume by 500 mL in patients with stool volumes of 500 mL. Progression of
GVHD was defined as an increase in the three day average stool volume by> 500 mL, or the
development of new abdominal pain (or new opioid analgesic requirements) or new intestinal
bleeding.
Criteria for mucosal response
Complete mucosal recovery was defined as the appearance of intact mucosa with at least 98%
of the luminal surface covered by epithelium. Partial response was defined as the appearance
of mostly intact mucosa with at least 80% improvement or less than 10% denuded. Limited
response was retrospectively designated to describe visible improvement that was less than
partial response. Failure to respond was defined as failure to meet partial response criteria
within 60 days.
Termination of the study
Termination of the study was required if none of the initial 6 patients showed complete or par-
tial functional or mucosal anatomic interim recovery at 4 weeks of lithium administration.
Continuation of the study was also subject to institutional review board monitoring of adverse
events.
Li to restore barrier function in GVHD
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Timing of events
The timing of the baseline endoscopy diagnostic of denuded mucosa, or baseline endoscopy
prior to enrollment in patients without denuded mucosa, is indicated as days after HCT. The
onset of lithium administration is indicated as days after baseline endoscopy. The timing of
subsequent events, including GVHD response and survival, is indicated as days after the onset
of lithium administration.
Statistical plan
The statistical plan called for a descriptive evaluation of the findings, since the trial had an
open label pilot design in which the timing of initiation of lithium therapy, the duration of
therapy and the frequency and timing of endoscopic reexaminations were at the clinical discre-
tion of the patient care team and were not prescribed by the protocol.
Comparison to historical results: The statistical considerations called for an assessment of
survival and indicated that historical survival results would be used informally as a basis for
judging the merits of more formal studies to evaluate the efficacy of lithium. To that end, the
data from two large FHCRC cohorts reported by Gooley et al [51] and Castilla-Llorente et al
[1] are retrospectively cited in the discussion section. Gooley et al reviewed the overall mortal-
ity in 1148 consecutive transplants at the FHCRC from 2003 to 2007. Castilla-Llorente et al
reviewed the incidence and associated mortality of stage 3–4 intestinal GVHD among 1465
consecutive transplants (1447 adults) at the FHCRC in the 6 years from 2000 to 2005.
Results
Patient characteristics
Patient characteristics are presented in Table 1. There were 13 women and 7 men of median
age 49.5 years (range 22–63 years) who were enrolled and eligible for evaluation of outcome.
The median time from HCT to enrollment was 90 days (range 22–800 days). The patients
were treated with corticosteroids at a prednisone- equivalent dose of 2 mg per kilogram per
day on or before the first day of lithium (n = 18) or within 4 days afterwards (n = 2). Sixteen
had steroid-refractory GVHD at the onset of lithium administration, and 4 developed steroid-
refractory GVHD during follow-up. Seventeen of the 20 patients had endoscopically docu-
mented denuded mucosa in the duodenum alone (n = 7), the colon alone (n = 7) or both
(n = 3). Three patients had intact mucosa.
Response after administration of lithium
Table 2 summarizes the systemic agents given for prevention or treatment of GVHD. Ten of
the 20 patients, 50%, had a CR of intestinal GVHD, of whom 8 survived >1 year (median 5
years, range 1.9 to>7 years) after the onset of lithium administration (Table 3). Ten patients
who did not have CR died with severe GVHD within 3 months. Baseline parameters that dif-
fered between patients who did and did not achieve a sustained CR and survival past 1 year
included the interval time between the onset of lithium administration and the baseline endos-
copy (a treatment variable at baseline), and the timing of initiation of salvage therapy for
GVHD before the onset of lithium administration (a presumed measure of the duration of
refractory GVHD at baseline).
In 12 patients, lithium administration was started within 3 days of the baseline endoscopy
and the diagnosis of denuded mucosa. Eight of these 12 patients, 67%, had a CR and survived
for more than 1 year. Among the patients who started Li more than 3 days after the baseline
endoscopy, 2 had a CR, but none survived 1 year.
Li to restore barrier function in GVHD
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In 7 patients, treatment of refractory GVHD with salvage therapy was started 7 or more
days (range 7–40 days) before the onset of lithium administration. One of these 7 patients had
a CR, but none survived 1 year. Use of salvage therapy, lacking established efficacy and safety
profile, was reserved for patients with steroid refractory GVHD deemed unlikely to respond to
continued standard treatment. This subset of 7 patients had persistent refractory disease dur-
ing salvage therapy before the onset of lithium administration. In contrast, none of the 8
patients who survived more than 1 year had been treated with salvage therapy before the onset
of lithium administration (Table 4).
Duration of lithium administration
Lithium was administered for a median of 30 days (range 7–172 days). Only 11 patients took
lithium for the planned 28 day minimum duration of administration (median duration, 44
days). Among the other 9 patients, administration of lithium was discontinued before day 28
due to toxicity or perceived inefficacy. Among the 3 patients who died prior to day 28, admin-
istration of lithium had already been discontinued 3, 11 and 19 days earlier. There were no 1
year survivors among patients who took lithium for less than 19 days. Seven of the eight 1 year
survivors took lithium for 30 or more days.
Table 1. Patient characteristics.
Patient Diagnosis HLA Matching Myeloablative
conditioning regimen
Original GVHD
prophylaxis
lithium start
day after HCT
Site denuded
D C
1 NHL M N CSP/MMF 34 Y Y
2 ALL MM Y Tac/MTX 45 N Y
3 AML M Y Tac/MTX 133 N Y
4 NHL M N Tac/MMF 105 N Y
5 AML MM (CB) Y CSP/MMF 48 Y N
6 AML M Y Tac/MTX 215 Y N
7 MM H N Cy/Tac/MMF 110 N Y
8 CML M N CSP/MMF 138 N Y
9 MM MM N CSP/MMF 140 N Y
10 AML MM N CSP/MMF 54 Y N
11 NHL MM N CSP/MMF 32 Y Y
12 ALL MM Y Tac/MTX 151 N Y
13 ALL MM Y Tac/MTX 40 Y N
14 MDS M Y Tac/MTX 103 Y Y
15 CML M Y Tac/MTX 77 Y N
16 AML MM Y Tac/MTX 22 Y N
17 AML MM Y Tac/MTX 22 Y N
18 AA M Y CSP/MMF 42 N N
19 PNH M Y Tac/MTX 134 N N
20 CLL MM N CSP/MMF 49 N N
D, indicates duodenum; C, colon; AA, aplastic anemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CB, cord blood; CLL, chronic
lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; NHL, non-Hodgkin
lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; HLA: M, matched; MM, mismatched; H, haploidentical. CSP, cyclosporine; Cy, cyclophosphamide;
MTX, methotrexate; and Tac, tacrolimus; Y, yes; N, no.
https://doi.org/10.1371/journal.pone.0183284.t001
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Mucosal recovery in patients with documented denuded intestinal
mucosa (Table 5)
The estimated extent of mucosal denudation at baseline was similar in patients who survived
more than one year and in those who did not. Specifically, very extensive mucosal denudation,
far exceeding entry criteria, was seen at baseline in 7 of the 8 patients who survived more than
1 year, with almost complete denudation of the visualized second and third portion of the
duodenum in 2 patients and extensive denudation of most of the visualized colon (sigmoid,
descending and transverse) in 6 patients (Fig 2). Follow-up endoscopic evaluations were lim-
ited because patients were examined endoscopically only for clinical indications. The earliest
mucosal PR was observed during week 2 after the onset of lithium administration, and the ear-
liest CR was observed during week 6. Five of the 6 patients with mucosal PR survived for at
least 9 months. All 4 patients with mucosal CR (including 3 with a prior PR) survived more
than a year. CR is assumed in the 4 long-term survivors who did not have a follow-up endo-
scopic evaluation during the study period.
Adverse events
Lithium trough serum concentrations remained below 1.0 mEq/L (therapeutic range 0.5 to
1.50 mEq/L) in all but 2 patients who reached maximal concentrations of 1.04 and 1.27 mEq/
L. Patients commonly experienced some degree of fatigue, decreased level of attention, somno-
lence or flattened affect (Table 6). The changes were considered to be related to lithium, but
Table 2. Systemic agents given for the prevention or treatment of GVHD.
Patient GVHD prophylaxis at start of lithium GVHD treatment in addition to Prednisone, 2mg/kg/d*
(days before -, or after, lithium start)
Number of salvage agents given 7 days before lithium
1 CSP MTX (1) Pento (38) 0
2 Tac rATG (0) 0
3 Tac MMF (-8) Inflix (2) Sirol (45) 0
4 Tac/MMF MMF (-17)‡ rATG (1) Sirol (74)† 0
5 MMF Tac (-21)† rATG (12) Sirol (47) 0
6 None Tac (-32) MMF (0) 0
7 Tac/MMF rATG (4) 0
8 CSP MMF (-19) CSP (-11)‡ Pento (0) 0
9 CSP MTX (–40) MMF (-40) Tac (13) Etan (19) Inflix (80) 0
10 CSP/MMF hATG (-14) MSC (-14) Inflix (14) Tac (15) Sirol (16) 2
11 CSP/MMF rATG (-7) Inflix (2) Sirol (10) 1
12 Tac rATG (-3) MMF (12) 0
13 Tac Inflix (-7) Pento (0) rATG (9) MMF (30)† Sirol (30)† 1
14 Tac rATG (2) Inflix (17) 0
15 None Tac (-27) Inflix (-20) ECP (-7) MMF (23) 2
16 Tac Alemt (-1) MMF (8) 0
17 MMF rATG (5) Alemt (7)¶ 0
18 CSP/MMF rATG (-8) Inflix (5) 1
19 None Inflix (-40) MMF (-34) ECP (-17) Sirol (-17) rATG (11) 2
20 CSP/MMF rATG (-9) 1
Alemt indicates alemtuzumab; Etan, etanercept; Inflix, infliximab; MSC, mesenchymal stem cell versus placebo study; and Pento, pentostatin. “Salvage
therapy” agents are designated in italics (see Methods).
†added as substitute for another drug;
‡was on taper, dose increased.
¶alemtuzumab substituted for ATG due to ATG toxicity.
https://doi.org/10.1371/journal.pone.0183284.t002
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were likely multifactorial in at least six of the patients. Two patients experienced multifactorial
severe somnolence during intensive care. Mild intermittent tremor, possibly related to lithium,
was seen in one patient with baseline intermittent tremor attributed to tacrolimus. All patients
received medications with overlapping toxicity profiles. Common concomitant medications
included opioids, benzodiazepines, phenothiazines, calcineurin inhibitors. Administration of
lithium was discontinued due to elevated liver function tests and skin blistering in two patients
with documented severe GVHD of the liver and skin, respectively. Other causes for discontin-
uing lithium administration included polyuria (in a patient with preceding polyuria) and leu-
kocytosis, both of which were multifactorial in origin. No grade 3 signs or symptoms were
Table 3. Outcomes after lithium administration.
Patient lithium start day after
endoscopy
lithium administration
duration, days
Intestinal GVHD
Response
Survival (S) at 2 years or day
expired*
Causes of death
1 0 56 CR S
2 0 43 CR S
3 1 57 CR S Relapse (1730†)
1767*
4 2 44 CR S Relapse (611†, 2151†)
2181*
5 3 108 CR S
6 3 40 CR S
7 3 30 CR S
8 1 19 CR 714 cGVHD, BOS
9 7 172‡ CR 302 BOS, cGVHD
10 0 25 NR 39 GVHD, CMV, Infection
11 5 31 NR 33 MOF, GVHD, Infection
12 6 19 PR 58 Liver GVHD, Infection
13 0 7 NR 65 DAH, GVHD, Infection
14 9 34 NR 63 GVHD, Infection
15 22 56 NR 85 GVHD
16 2 8 NR 27 HUS, GVHD, MOF
17 3 8 NR 41 GVHD
18 10 8 NR 11 GVHD
19 11 13 NR 24 GVHD, CMV
20 10 18 CR 210 Infection, GVHD
NR indicates no response; ARDS, adult respiratory distress syndrome; BOS, bronchiolitis obliterans syndrome; DAH, diffuse alveolar hemorrhage; HUS,
hemolytic uremic syndrome; cGVHD, chronic GVHD; CMV, cytomegalovirus; and MOF, multiorgan failure.
*day expired.
†day of recurrent malignancy after start of lithium.
‡lithium withheld day 8–19
https://doi.org/10.1371/journal.pone.0183284.t003
Table 4. Characteristics of 1-year survivors and non-survivors.
Characteristic Survivors
(N = 8)
Nonsurvivors
(N = 12)
lithium started 3 days after endoscopic diagnosis of denuded mucosa, N (%) 8 (100) 4 (33)
Salvage therapy for refractory GVHD 7 days before lithium, N (%) 0 (0) 7 (58)
lithium started 3 days after endoscopy and no salvage therapy for GVHD 7 days before lithium, N (%) 8 (100) 2 (17)
lithium started 3 days after endoscopy and given for 19 days, N (%) 8 (100) 1 (8)
https://doi.org/10.1371/journal.pone.0183284.t004
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considered to be exclusively attributable to lithium. Three patients (15%) had recurrent malig-
nancy. One had leukemia on day 5 after the onset of lithium administration and was taken off
study (but is included in the toxicity monitoring, Fig 1). A second patient had recurrent extra-
nodal diffuse large B cell lymphoma on day 611 and again on day 2151. The third patient had
recurrent AML with a chloroma on day 1730.
Discussion
We conducted an observational study of lithium in patients with severe steroid refractory
intestinal GVHD with a focus on those with extensively denuded mucosa. The study was based
on the premise that restoration of mucosal barrier function was a prerequisite to resolution of
systemic GVHD in this subset of patients. The primary intent was to evaluate the potential
merit of further studies of lithium and to obtain preliminary data for use in the design of a
structured next phase study. Due to concerns of safety and lack of preclinical data supporting
use of lithium in this context, the study parameters, including timing and duration of lithium
administration, were left to the discretion of the primary providers and patients. To minimize
the inherent bias in the evaluation of unstructured data, we chose survival to be the main out-
come measure to be used as a basis for judging the merits of more formal studies lithium. Simi-
larly we focused on objective and precise baseline parameters including the date of diagnosis
of extensively denuded intestinal mucosa (n = 17), interval time to the onset of lithium admin-
istration, and date of initiation of salvage therapy for steroid refractory GVHD.
The study data was reviewed for differences between responders and non-responders that
might guide study eligibility criteria for a next phase clinical trial. We observed that all eight
patients who survived one year had two characteristics in common: administration of lithium
was started within 3 days after the endoscopic diagnosis of denuded mucosa and salvage ther-
apy for refractory GVHD was not administered before the onset of lithium administration.
Other measures of GVHD severity which may have contributed to variation in outcomes
were not clearly different between survivors and non-survivors, all of whom had a severe clini-
cal course. These measures included volume of diarrhea, severity of abdominal pain, and the
incidence of end organ compromise, hypoalbuminemia, and fungal and viral infections,
including CMV.
Table 5. Mucosal response among patients with denudation*.
Response† Week after the onset of lithium administration
2–3 4 5 6–7 9–11
Number of patients examined 8 (6D, 5C) 2 (1D, 1C) 1 (D) 3 (1D, 3C) 4 (3C, 2D)
No response, N (sites) 3 (3D, 1C)
Regenerative changes, N (sites) 3 (2D, 2C)
Limited response, N (sites) 1 (C)
Partial response, N (sites) 2 (1D, 2C) 1 (D) 1 (D) 2 (C)
Complete response, N (sites) 3 (1D, 3C) 2 (2D, 1C)
D, duodenum; C, colon.
*3 patients with denuded mucosa did not have a follow-up endoscopic evaluation.
†A total of 18 endoscopies (esophagogastroduodenoscopy, sigmoidoscopy/partial colonoscopy, or both) were performed in 14 patients. No response, no
change; regenerative changes, diffuse foci of regenerative mucosa; limited response (LR), clearly visible improvement, less than PR; partial response (PR),
more than 80% improvement; complete response (CR), more than 99% intact at 1 exam on week 6, normal in 4. Three patients had serial follow-up exams:
1) PR week 2, CR with abnormal mucosa week 6, CR week 10; 2) LR week 4, PR week 11; 3) PR week 5, CR week 11.
https://doi.org/10.1371/journal.pone.0183284.t005
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Lithium was administered in an effort to promote mucosal regeneration. However, serial
endoscopic evaluations at key time points could not be performed, and therefore, the rate or
degree of mucosal recovery could not be adequately assessed.
Serum lithium concentrations were maintained at low levels due to concern for toxicity.
These observations raise the question of whether the lithium doses were adequate for optimal
evaluation of efficacy. The optimal dose of lithium remains to be determined.
Fig 2. Endoscopic appearance (A, B) and histology (C-F) of denuded mucosa in the colon (left) and duodenum (right) at
baseline in two patients who experienced CR of GVHD and survived more than one year. Surface epithelium and crypts are
virtually absent in the colon and duodenum and villi are absent in the duodenum (C,D H&E x10; E,F H&E x20; bar size = 100uM).
https://doi.org/10.1371/journal.pone.0183284.g002
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Lithium appeared to be well tolerated, but symptoms attributable to lithium toxicity were
difficult to assess in this non-randomized population of critically ill and highly symptomatic
patients who have high, > 70%, reported incidence of delirium events [52]. The main reported
toxicities were fatigue, dulled sensorium, and flattened affect. Lithium can cause decreased
urinary concentrating ability, and this effect should be considered in patients with renal insuf-
ficiency. Use of lithium to upregulate a component of Wnt signaling raised concern for recur-
rence of hematologic malignancy. Three patients had recurrent malignancy. The relapses
occurred either very early or very late, and the 15% rate was comparable to the reported 26%
rate among 1148 consecutive transplants at the FHCRC during the years 2003–2007 [51].
Nonetheless, the potential effects of lithium on hematologic malignancy remain undefined.
The survival data compare favorably with the historical FHCRC and with other reported
survival data. Jamani et al reported less than 20% 2 year survival and less than 10% 5 year sur-
vival in a cohort of severe, grade 3–4 (stage 2–4), steroid refractory GVHD and similar median
survival in review of post year 2000 published studies [53–55]. A 2 year survival rate of 10%
was noted in 69 adults with steroid-refractory stage 3 or 4 intestinal GVHD (including all
endoscopic grades) in a cohort of 1447 allogeneic transplants at the FHCRC during the 6 years
preceding our study The 27 adults with grade 3 (on scale of 1–3) endoscopic appearance in the
duodenum or colon had 0% 1 year survival. The latter included 17 patients whose endoscopy
report included the word denuded. Similarly, Abraham et al reported 0% 5 year survival in
allogeneic HCT patients with intestinal GVHD and severe endoscopic appearance or very
severe histological appearance (mucosal sloughing) [56].
In our study of lithium, patients with severe steroid-refractory intestinal GVHD who
started lithium administration within 3 days of diagnosis of extensively denuded mucosa
(equivalent to extreme grade 3 endoscopic appearance) had a 67% survival at 1 year and 50%
survival at 5 years. This results was similar to the historical survival of the total cohort of trans-
planted adult patients at the FHCRC in the years 2003–2007 reported by Gooley et al. and
Table 6. Adverse events*.
Event N (%)
Mental status changes 10 (45)
Somnolence, fatigue 6 (27)
Confusion 3 (14)
Apathy 2 (9)
Polyuria 1 (5)
Leukocytosis 1 (5)
Nausea/vomiting 2 (9)
Reasons for discontinuation of Li+
Mental status changes 7 (32)
Response 7 (32)
Lack of response 2 (9)
Blistering of skin 1 (5)
Elevated liver function tests 1 (5)
Leukocytosis 1 (5)
Polyuria 1 (5)
Low Li+ serum levels 1 (5)
Change to comfort care 1 (5)
*Adverse events observed in patients who received lithium carbonate. No grade 3 toxicity was attributable
exclusively to lithium administration.
https://doi.org/10.1371/journal.pone.0183284.t006
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better than the expected near 0% survival previously observed in this subset of patients compa-
rable to those enrolled in the current study. Those who started lithium administration within 3
days of diagnosis of denuded mucosa and less than 7 days from salvage therapy for GVHD,
had an 80% 1 year survival and 60% 5 year survival. Although the observational study design
lacked the statistical power and controls to determine efficacy of lithium, the factual observa-
tions appear to support the conduct of a randomized study of lithium in this patient subset.
Based on the above observations, entry criteria for a structured clinical trial of lithium
would include patients with severe steroid-refractory GVHD and endoscopically documented
denuded mucosa within less than 7 days from the onset of salvage therapy. Administration of
lithium would be initiated within 3 days of endoscopic diagnosis and would be continued for
at least 19 days (optimally for more than 28 days) in those without limiting toxicity. The 8
patients who met all of these criteria survived for a median of more than 5 years at last follow-
up.
Following the completion of our study, the underlying hypotheses were substantiated by
two animal experiments demonstrating that induction of Wnt signaling by R-spondin1, and
GSK3 inhibition can ameliorate or prevent fatal GVHD [31,50]. In addition, a large body of lit-
erature further established the role of Wnt signaling in mucosal regeneration and explored the
effect of GSK3 on innate and adaptive immune responses [36–42,44–49,57–61]. Studies of
GSK3 inhibition in experimental inflammatory conditions such as colitis, arthritis, and neu-
roinflammatory disorders remain exploratory but strongly suggest that GSK3 may be a clini-
cally useful therapeutic target [36–39,46–50,57–63]. To our knowledge, this is the first study in
humans to target GSK3 and focus on repair of mucosal barrier dysfunction in the pharmaco-
logical management of GVHD. The severe clinical course of GVHD in patients with disrupted
mucosal barrier supports the need for further research in this field.
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